The press releases published by TME Pharma (formerly NOXXON Pharma) and contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. TME Pharma disavows any obligation to update the information contained in such press releases after the date of their issuance.
Filter: NOX-A12 (olaptesed) | NOX-E36 (emapticap) | all
| Date | Title | Download | ||
| 2024, November 23 09:00 a.m. | TME Pharma announces poster presentation by U.S. National Cancer Institute on CXCL12 inhibition by NOX-A12 in glioblastoma at 2024 SNO Annual Meeting |  |  | |
| 2024, October 31 08:00 a.m. | TME Pharma awarded €2.4 million German Federal grant to support NOX-A12 Phase 2 trial in brain cancer | | | |
| 2024, September 19 08:00 a.m. | TME Pharma announces acceptance of the NCI’s abstract on NOX-A12 in glioblastoma for presentation at the SNO 2024 Annual Meeting | | | |
| 2024, September 16 08:00 a.m. | TME Pharma announces oral presentation at ESMO Congress 2024 with updated results from NOX-A12 GLORIA Phase 1/2 trial in glioblastoma | | | |
| 2024, July 17 08:00 a.m. | TME Pharma announces oral presentation of NOX-A12 GLORIA Phase 1/2 trial in glioblastoma at ESMO Congress 2024 | | | |
| 2024, June 17 05:30 p.m. | TME Pharma announces publication in Nature Communications of biomarker data from NOX-A12 GLORIA Phase 1/2 trial in glioblastoma | | | |
| 2024, April 23 08:00 a.m. | TME Pharma announces 33% of patients receiving NOX-A12 in combination with bevacizumab and radiotherapy achieve two-year survival in GLORIA Phase 1/2 trial in brain cancer | | | |
| 2024, April 02 08:00 p.m. | TME Pharma receives US FDA Fast Track designation for lead asset NOX-A12 in brain cancer | | | |
| 2024, March 05 08:00 a.m. | TME Pharma announces FDA clearance of Investigational New Drug (IND) application for NOX-A12 Phase 2 trial in brain cancer | | | |
| 2024, February 02 08:00 a.m. | TME Pharma announces final median overall survival data reaching 19.9 months for NOX-A12 combination regimen in GLORIA brain cancer trial and survival rate 10-fold greater than standard of care | | | |
| 2024, January 09 06:00 p.m. | TME Pharma announces successful advice meeting with US Food and Drug Administration on NOX-A12 development in brain cancer | | | |
| 2023, December 20 08:00 a.m. | TME Pharma announces further improvement in median overall survival at 19 months follow-up in GLORIA brain cancer trial | | | |
| 2023, November 18 08:00 a.m. | TME Pharma announces additional data from NOX-A12 combination regimen in brain cancer presented at SNO 2023 Annual Meeting | | | |
| 2023, October 20 08:00 a.m. | TME Pharma announces further improvement in overall survival at 18 months to 67% for NOX-A12 combination regimen in brain cancer | | | |
| 2023, October 16 08:00 a.m. | TME Pharma announces publication of ESMO Congress 2023 abstract on the ongoing NOX-A12 GLORIA Phase 1/2 trial in glioblastoma | | | |
| 2023, October 10 08:00 a.m. | TME Pharma provides positive update on 18-month survival for NOX-A12 combination regimen in brain cancer and provides strategic update including decision to engage with US FDA | | | |
| 2023, September 22 08:00 a.m. | TME Pharma announces selection of two clinical abstracts on the ongoing NOX-A12 GLORIA Phase 1/2 trial in glioblastoma for presentation at ESMO 2023 congress and SNO 2023 Annual Meeting | | | |
| 2023, September 13 08:00 a.m. | NOX-A12 combination regimen with bevacizumab: 17-month survival rate exceeds all relevant competitor treatments against most severe form of adult brain cancer | | | |
| 2023, July 13 08:00 a.m. | TME Pharma provides positive data update on best response to therapy with first complete response in GLORIA trial in glioblastoma, bringing 50% of patients in expansion arm to complete or near-complete response | | | |
| 2023, June 28 08:00 a.m. | TME Pharma announces positive 15-month survival data from GLORIA expansion arm evaluating NOX-A12 in combination with radiotherapy and bevacizumab in glioblastoma | | | |
| 2023, June 15 06:00 p.m. | TME Pharma receives Investigational New Drug (IND) approval for NOX-A12 from the US FDA | | | |
| 2023, May 26 08:00 a.m. | TME Pharma announces publication of ASCO 2023 abstract disclosing new biomarker data from NOX-A12 GLORIA Phase 1/2 trial in glioblastoma | | | |
| 2023, May 25 06:00 p.m. | TME Pharma provides positive clinical update and 14-month survival data from GLORIA expansion arm evaluating NOX-A12 in combination with radiotherapy and bevacizumab in glioblastoma | | | |
| 2023, April 27 08:00 a.m. | TME Pharma announces new data from NOX-A12 GLORIA Phase 1/2 study in glioblastoma to be presented at ASCO annual meeting in June 2023 | | | |
| 2023, March 27 08:00 a.m. | TME Pharma announces 83% of glioblastoma patients still alive after 12 months on study (median) in GLORIA expansion arm evaluating NOX-A12 in combination with radiotherapy and bevacizumab | | | |
| 2023, February 24 08:00 a.m. | TME Pharma CEO message | | | |
| 2023, January 23 08:00 a.m. | TME Pharma provides clinical update on the GLORIA expansion arm testing NOX-A12 in combination with radiotherapy and bevacizumab in patients with glioblastoma | | | |
| 2022, November 19 01:30 a.m. | Positive updated interim results from NOX-A12 GLORIA Phase 1/2 in brain cancer presented at the Society for Neuro-Oncology 2022 Annual Meeting | | | |
| 2022, November 14 08:00 a.m. | TME Pharma to host key opinion leader webinar | | | |
| 2022, November 11 01:00 p.m. | TME Pharma announces publication of abstract disclosing positive interim results from bevacizumab expansion arm of NOX-A12 GLORIA Phase 1/2 brain cancer clinical trial additional and updated data to be presented during SNO 2022 Annual Meeting on Nov 18, 2022 | | | |
| 2022, September 20 06:00 p.m. | TME Pharma announces upcoming presentation at the Society for Neuro-Oncology Annual Meeting 2022 | | | |
| 2022, August 26 08:00 a.m. | Safety confirmed of NOX-A12 and pembrolizumab combination in GLORIA Phase 1/2 brain cancer study | | | |
| 2022, August 03 08:00 a.m. | TME Pharma announces enrollment of first patient in pembrolizumab expansion arm of NOX-A12 GLORIA Phase 1/2 brain cancer clinical trial | | | |
| 2022, June 23 08:00 a.m. | NOXXON announces updated development strategy following strong clinical benefit observed with NOX-A12 in combination with radiotherapy and bevacizumab in brain cancer | |  | |
| 2022, June 13 08:00 a.m. | NOXXON enters into collaboration with US National Cancer Institute to characterize effects of lead compounds on brain tumors | | | |
| 2022, June 05 03:00 p.m. | NOXXON presents full top-line results from NOX-A12 Phase 1/2 GLORIA trial in glioblastoma at the 2022 ASCO Annual Meeting | | | |
| 2022, June 01 08:00 a.m. | NOXXON to host key opinion leader webinar on GLORIA study top-line results of NOX-A12 and radiotherapy combination in first-line glioblastoma | | | |
| 2022, May 26 11:00 p.m. | NOXXON announces presentation of NOX-A12 Phase 1/2 data in glioblastoma at the 2022 ASCO Annual Meeting and invitation to a dedicated KOL event | | | |
| 2022, April 06 08:00 a.m. | Top-line results from NOXXONs NOX-A12 Phase 1/2 GLORIA trial in brain cancer to be presented during 2022 ASCO Annual Meeting | | | |
| 2022, March 24 08:00 a.m. | NOXXON announces top-line data of Phase 1/2 GLORIA study with NOX-A12 in partially resected or biopsy-only MGMT-unmethylated newly-diagnosed glioblastoma patients | | | |
| 2022, January 07 08:00 a.m. | NOXXON provides progress update on the expansion arms of the Phase 1/2 GLORIA trial with NOX-A12 in brain cancer patients | | | |
| 2022, January 05 07:30 p.m. | NOXXON provides update on evaluation of NOX-A12 in non-oncology indication by a leading international pharma company | | | |
| 2022, January 03 06:00 p.m. | Corrected press release: NOXXON secures €17 million expansion of equity-linked facility with Atlas to advance NOX-A12 in glioblastoma and pancreatic cancer programs | | | |
| 2021, December 29 06:00 p.m. | NOXXON secures Euro 17 million expansion of equity-linked facility with Atlas to advance NOX-A12 in glioblastoma and pancreatic cancer programs | | | |
| 2021, December 07 08:00 a.m. | NOXXON announces enrolment of first patient in the expansion of the NOX-A12 Phase 1/2 trial in brain cancer | | | |
| 2021, December 02 08:00 a.m. | NOXXON summarizes essential points from Key Opinion Leader event on NOX-A12 & radiotherapy combination in brain cancer held on November 23, 2021 with Dr Frank A. Giordano | | | |
| 2021, November 22 08:00 a.m. | NOXXON: New Phase 1/2 data on NOX-A12 & radiotherapy combination in brain cancer presented at the Society for Neuro-Oncology Annual Meeting 2021 | | | |
| 2021, November 16 08:00 a.m. | NOXXON to host Key Opinion Leader webinar on NOX-A12 and radiotherapy combination: a differentiated and promising new approach to treating brain cancer | | | |
| 2021, November 12 08:00 a.m. | New positive interim results from NOXXON’s Phase 1/2 GLORIA trial in brain cancer to be presented at the Society for Neuro-Oncology Annual Meeting 2021 | | | |
| 2021, November 03 08:00 a.m. | NOXXON provides update on timing for upcoming trials of NOX-A12 in pancreatic and brain cancer | | | |
| 2021, October 19 08:00 a.m. | NOXXON announces planned expansion of Phase 1/2 NOX-A12 brain cancer trial | | | |
| 2021, October 06 08:00 a.m. | NOXXON Pharma announces upcoming oral presentation at the Society for Neuro-Oncology Annual Meeting 2021 | | | |
| 2021, September 22 08:00 a.m. | NOXXON enrolls last brain cancer patient in dose escalation portion of GLORIA study and confirms phase 1/2 read-out in Q1 2022 | | | |
| 2021, August 05 08:00 a.m. | NOXXON provides update on NOX-A12 clinical programs | | | |
| 2021, July 21 06:00 p.m. | NOXXON Pharma enters second clinical collaboration with MSD to evaluate NOX-A12 in combination with KEYTRUDA (pembrolizumab) in upcoming Phase 2 pancreatic cancer study | | | |
| 2021, June 08 08:00 a.m. | CORRECTED PRESS RELEASE: NOXXON announces positive results from second cohort in Phase 1/2 NOX-A12 brain cancer trial | | | |
| 2021, June 01 06:00 p.m. | NOXXON announces manufacturing of NOX-A12 drug substance for future clinical trials and issuance of convertible bonds under financing agreement with Atlas | | | |
| 2021, June 01 08:00 a.m. | NOXXON announces positive results from second cohort in Phase 1/2 NOX-A12 brain cancer trial | | | |
| 2021, May 10 06:00 p.m. | NOXXON announces Data Safety Monitoring Board validates NOX-A12 highest dose in Phase 1/2 brain cancer trial | | | |
| 2021, April 14 06:00 p.m. | NOXXON successfully completes patient recruitment in Phase 1/2 brain cancer study of NOX-A12 plus radiotherapy | | | |
| 2021, March 12 08:00 a.m. | Data Safety Monitoring Board confirms safety and validates recruitment of last patients in final high-dose cohort of NOX-A12 in Phase 1/2 brain cancer study | | | |
| 2021, February 15 06:00 p.m. | NOXXON enrolls first patient in the high dose cohort of trial combining NOX-A12 with radiotherapy in newly diagnosed brain cancer | | | |
| 2021, February 08 06:00 p.m. | NOXXON appoints leading pancreatic cancer experts to Scientific Advisory Board | | | |
| 2020, December 29 08:00 p.m. | NOXXON announces initiation of NOX-A12 manufacturing for future clinical studies | | | |
| 2020, November 09 08:00 a.m. | NOXXON announces that Data Safety Monitoring Board validates further NOX-A12 dose escalation in Phase 1/2 brain cancer study | | | |
| 2020, October 28 08:00 a.m. | NOXXON announces completion of 6-month therapy for low-dose cohort in Phase 1/2 brain cancer study of NOX-A12 plus radiotherapy | | | |
| 2020, October 20 08:00 a.m. | NOXXON announces three additional clinical centers to recruit patients for NOX-A12 brain cancer trial | | | |
| 2020, October 14 08:00 a.m. | NOXXON announces successful completion of patient recruitment for second dose cohort in phase 1/2 brain cancer study of NOX-A12 plus radiotherapy | | | |
| 2020, September 17 09:00 a.m. | NOXXON presents final clinical data from phase 1/2 NOX-A12 / Keytruda combination trial in colorectal and pancreatic cancer at the ESMO virtual congress 2020 | | | |
| 2020, July 24 8:00 a.m. | NOXXON announces first brain cancer patient from second dose cohort reaches 4 weeks of treatment with NOX-A12 combined with radiotherapy | | | |
| 2020, June 30 6:00 p.m. | NOXXON enrolls first patient in the second dose cohort of trial combining NOX-A12 with radiotherapy in newly diagnosed brain cancer | | | |
| 2020, April 27 6:00 p.m. | NOXXON presents latest clinical data from the Phase 1/2 NOX-A12 / Keytruda combination trial in colorectal and pancreatic cancer at the AACR Virtual Annual Meeting 2020 | | | |
| 2020, April 24 8:00 a.m. | NOXXON announces that Data Safety Monitoring Board validates NOX-A12 dose escalation in Phase 1/2 brain cancer study | | | |
| 2020, April 14 6:00 p.m. | NOXXON to present latest clinical data from the NOX-A12 / KEYTRUDA combination trial in colorectal and pancreatic cancer at the AACR Virtual Annual Meeting 2020 | | | |
| 2020, April 02 8:00 a.m. | NOXXON announces completion of patient recruitment for the first dose cohort in the phase 1/2 brain cancer study of NOX-A12 plus radiotherapy | | | |
| 2019, December 20 8:00 a.m. | NOXXON announces first brain cancer patient reaches 10 weeks of treatment with NOX-A12 plus radiotherapy | | | |
| 2019, October 24 6:00 p.m. | NOXXON publishes interim 2019 results | | | |
| 2019, October 16 8:00 a.m. | NOXXON enrolls first patient in the phase 1/2 clinical trial combining NOX-A12 with radiotherapy in newly diagnosed brain cancer | | | |
| 2019, September 29 12:00 p.m. | NOXXON presents latest clinical data from Phase 1/2 NOX-A12 / Keytruda combination trial at the ESMO congress | | | |
| 2019, September 18 8:00 a.m. | NOXXON to present latest clinical data from NOX-A12 / Keytruda combination trial at the ESMO congress | | | |
| 2019, September 12 6:00 p.m. | NOXXON initiates patient recruitment for phase 1/2 clinical trial combining NOX-A12 & radiotherapy for the treatment of brain cancer patients | | | |
| 2019, June 24 8:00 a.m. | NOXXON announces leading international pharma to evaluate NOX-A12 in new indication | | | |
| 2019, April 01 7:00 p.m. | NOXXON presents updated results from Phase 1/2 NOX-A12 / Keytruda combination trial at AACR 2019 | | | |
| 2019, February 28 7:00 p.m. | NOXXON to present latest clinical data from NOX-A12 / Keytruda combination trial at the 2019 AACR Annual Meeting | | | |
| 2019, February 27 6:00 p.m. | NOXXON files application for phase 1/2 clinical trial combining NOX-A12 & radiotherapy for the treatment of brain cancer | | | |
| 2018, December 14 12:30 p.m. | NOXXON announces key findings that NOX-A12 plus Keytruda induces an immune response and results in clinical benefit for patients | | | |
| 2018, December 10 8:00 a.m. | NOXXON to present latest clinical data from NOX-A12 / Keytruda combination trial at ESMO immuno-oncology congress on December 13-16, 2018 | | | |
| 2018, November 21 8:00 a.m. | NOXXON to launch NOX-A12 with radiotherapy clinical trial in patients with brain cancer | | | |
| 2018, October 26 8:00 a.m. | NOXXON to present top-line efficacy data from NOX-A12 / Keytruda combination trial in December as planned at ESMO Immuno-Oncology Conference | | | |
| 2018, October 02 6:00 p.m. | NOXXON presents top-line data from NOX-A12 monotherapy part of ongoing metastatic colorectal and pancreatic cancer trial | | | |
| 2018, September 19 8:00 a.m. | NOXXON to present clinical trial data at Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference 'Translating Science into Survival' | | | |
| 2018, September 03 8:00 a.m. | NOXXON announces completion of patient recruitment in ongoing NOX-A12 pancreatic and colorectal cancer trial | | | |
| 2018, June 28 8:00 p.m. | NOXXON provides update on patient recruitment in ongoing NOX-A12 pancreatic and colorectal cancer trial | | | |
| 2018, May 29 8:00 a.m. | NOXXON provides clinical update prior to American Society of Clinical Oncology (ASCO) annual conference | | | |
| 2018, May 15 6:00 p.m. | NOXXON to present clinical trial update at BioEquity Europe | | | |
| 2017, October 03 | NOXXON Publishes Preclinical Proof-Of-Concept Data for Lead Compound NOX-A12 in Combination with Checkpoint Inhibitors | | | |
| 2017, September 28 | NOXXON provides update on ongoing phase 1/2 clinical trial with lead program NOX-A12 | | | |
| 2017, July 04 | NOXXON announces first patients treated in phase I/II clinical trial of NOX-A12 combined with Keytruda in metastatic pancreatic and colorectal cancer | | | |
| 2017, May 16 | NOXXON Pharma announces collaboration with National Center for Tumor Diseases in Heidelberg for NOX-A12/Keytruda phase 1/2 combination trial | | | |
| 2016, December 15 | NOXXON Pharma signs clinical immuno-oncology collaboration agreement with MSD to study NOX-A12 combined with Keytruda (pembrolizumab) in pancreatic and colorectal cancer | | | |
| 2016, December 05 | NOXXON Pharma announces new preclinical data showing synergy of lead compound NOX-A12 with natural killer (NK) Cell mediated therapies | | | |
| 2016, October 10 | NOXXON Pharma demonstrates synergies between NOX-A12 and therapies working through T cells or NK cells | | | |
| 2014, December 05 | Phase IIa Results for Spiegelmer Olaptesed Pegol (NOX-A12) in MM and CLL at 2014 American Society of Hematology (ASH) Conference | | | |
| 2014, September 26 | Cell Reports Publication on the Mechanism of Action of NOXXONs Anti-SDF-1 Spiegelmer Olaptesed Pegol (NOX-A12) in Preclinical Multiple Myeloma Models | | | |
| 2014, September 23 | NOXXON Spiegelmer receives FDA Orphan Drug Designation for Glioblastoma Treatment | | | |
| 2014, June 13 | NOXXON presents Updates on Phase II Studies with Olaptesed Pegol (NOX-A12) in CLL and MM and Lexaptepid Pegol (NOX H94) in Anemic Cancer Patients | | | |
| 2013, December 09 | NOXXON presenting at ASH 2013 | | | |
| 2012, September 26 | NOXXON Initiates Phase IIa Trial of anti-CXCL12/SDF-1 Spiegelmer NOX-A12 in Second Oncology Indication: Multiple Myeloma | | | |
| 2012, July 11 | NOXXON Initiates Phase IIa of anti-CXCL12/SDF-1 Spiegelmer NOX-A12 for Treatment of Chronic Lymphocytic Leukemia | | | |
| 2012, April 4 | NOXXONs NOX-A12 Delays Glioblastoma Recurrence in Preclinical Model | | | |
| 2011, December 12 | NOXXONs SDF-1 inhibitor NOX-A12 completes Phase I | | | |
| 2010, September 22 | NOXXON initiates multiple dose phase I clinical trial of SDF-1 inhibitor NOX-A12 | | | |
| 2010, May 3 | NOXXON Announces the Completion of the First-in-Human Clinical Trial with Spiegelmer NOX-A 12 | | | |
| 2009, November 2 | NOXXON Announces Initiation of First-in-Human Clinical Trial with Hematopoietic Stem Cell Mobilizing Spiegelmer NOX-A12 | | | |
| 2009, September 3 | NOXXON Is Awarded Research and Development Grant for First-in-Human Clinical Trial with Spiegelmer NOX-A12 | | | |